Total Payments
$16,365
2024 Payments
$1,432
Companies
21
Transactions
97
Medicare Patients
408
Medicare Billing
$52,313
Payment Breakdown by Category
Research$8,257 (50.5%)
Consulting$6,161 (37.6%)
Food & Beverage$1,315 (8.0%)
Other$597.15 (3.6%)
Education$34.66 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,257 | 17 | 50.5% |
| Consulting Fee | $6,161 | 4 | 37.6% |
| Food and Beverage | $1,315 | 72 | 8.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $597.15 | 2 | 3.6% |
| Education | $34.66 | 2 | 0.2% |
Payments by Type
Research
$8,257
17 transactions
General
$8,108
80 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $8,854 | 19 | $0 (2021) |
| GENZYME CORPORATION | $2,916 | 1 | $0 (2021) |
| AbbVie Inc. | $1,943 | 6 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,525 | 11 | $0 (2024) |
| Abbott Laboratories | $254.95 | 2 | $0 (2023) |
| Lilly USA, LLC | $116.57 | 8 | $0 (2023) |
| BeiGene USA, Inc. | $108.32 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $107.36 | 8 | $0 (2022) |
| Merck Sharp & Dohme LLC | $100.12 | 7 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $80.59 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,432 | 4 | AstraZeneca Pharmaceuticals LP ($1,387) |
| 2023 | $305.32 | 6 | Abbott Laboratories ($254.95) |
| 2022 | $272.44 | 15 | BeiGene USA, Inc. ($64.78) |
| 2021 | $7,198 | 10 | F. Hoffmann-La Roche AG ($4,238) |
| 2020 | $5,961 | 17 | F. Hoffmann-La Roche AG ($4,019) |
| 2019 | $725.87 | 11 | F. Hoffmann-La Roche AG ($597.15) |
| 2018 | $204.97 | 14 | Lilly USA, LLC ($47.85) |
| 2017 | $264.97 | 20 | TESARO, Inc. ($55.33) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Oncology | ||||||
| 07/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2023 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $134.49 | General |
| Category: Heart Failure | ||||||
| 03/19/2023 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $120.46 | General |
| Category: Heart Failure | ||||||
| 02/27/2023 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO, RETEVMO | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Oncology | ||||||
| 01/31/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $7.19 | General |
| Category: ONCOLOGY | ||||||
| 01/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Oncology | ||||||
| 11/08/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.35 | General |
| Category: Oncology | ||||||
| 11/01/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: Oncology | ||||||
| 10/21/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Oncology | ||||||
| 10/11/2022 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Oncology | ||||||
| 10/04/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2022 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Oncology | ||||||
| 08/23/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.31 | General |
| 07/30/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Oncology | ||||||
| 07/25/2022 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Oncology | ||||||
| 06/28/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $18.65 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $18.65 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P | F. Hoffmann-La Roche AG | $2,858 | 3 |
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children, STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $1,632 | 1 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | F. Hoffmann-La Roche AG | $1,381 | 3 |
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 | F. Hoffmann-La Roche AG | $1,240 | 6 |
| STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $662.88 | 2 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $484.36 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 46 | 88 | $44,130 | $6,977 |
| 2022 | 3 | 68 | 124 | $52,564 | $10,024 |
| 2021 | 7 | 131 | 186 | $73,575 | $17,468 |
| 2020 | 8 | 163 | 243 | $75,560 | $17,844 |
Total Patients
408
Total Services
641
Medicare Billing
$52,313
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 70 | $32,370 | $5,091 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 18 | $11,760 | $1,886 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 74 | $31,138 | $5,611 | 18.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 33 | $11,435 | $2,489 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 17 | $9,991 | $1,923 | 19.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 66 | $24,186 | $5,210 | 21.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $11,235 | $2,674 | 23.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 32 | $11,080 | $2,598 | 23.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 21 | $10,209 | $2,439 | 23.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $10,341 | $2,186 | 21.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 17 | $2,258 | $1,344 | 59.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 18 | $4,266 | $1,016 | 23.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 71 | $24,437 | $4,345 | 17.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 42 | $13,836 | $3,519 | 25.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 43 | $9,897 | $2,499 | 25.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $9,505 | $2,427 | 25.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 13 | 18 | $8,148 | $1,559 | 19.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 14 | $6,026 | $1,539 | 25.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 23 | 26 | $2,059 | $1,068 | 51.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 13 | 14 | $1,652 | $888.00 | 53.8% |
About Dr. Manish Patel, DO
Dr. Manish Patel, DO is a Internal Medicine healthcare provider based in Bloomington, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740204957.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manish Patel, DO has received a total of $16,365 in payments from pharmaceutical and medical device companies, with $1,432 received in 2024. These payments were reported across 97 transactions from 21 companies. The most common payment nature is "" ($8,257).
As a Medicare-enrolled provider, Patel has provided services to 408 Medicare beneficiaries, totaling 641 services with total Medicare billing of $52,313. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Bloomington, MN
- Active Since 07/27/2006
- Last Updated 01/15/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1740204957
Products in Payments
- ROZLYTREK (Biological) $4,019
- LIBTAYO (Biological) $2,916
- VENCLEXTA (Drug) $1,912
- Non-Covered Product (Drug) $597.15
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $254.95
- BRUKINSA (Drug) $108.32
- OPDIVO (Biological) $107.36
- IMFINZI (Biological) $83.44
- KEYTRUDA (Biological) $83.36
- GILOTRIF (Drug) $80.59
- CYRAMZA (Drug) $61.61
- TAGRISSO (Drug) $57.68
- ALIMTA (Drug) $54.96
- Vitrakvi (Drug) $50.21
- VARUBI (Drug) $40.52
- Cotellic (Drug) $39.35
- COSELA (Drug) $37.30
- XPOVIO (Drug) $34.07
- Abraxane (Drug) $33.44
- Venclexta (Drug) $30.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bloomington
Desiree Ortiz-Cruz, Md, MD
Internal Medicine — Payments: $191,757
Internal Medicine $191,757
Dr. Joan Crawford, Do, DO
Internal Medicine — Payments: $186,460
Internal Medicine $186,460
Dr. Omar Khokhar, Md, MD
Internal Medicine — Payments: $133,324
Internal Medicine $133,324
Dr. William Schmalz, Md, MD
Internal Medicine — Payments: $131,004
Internal Medicine $131,004
Avani Desai, Md Mbbs, MD MBBS
Internal Medicine — Payments: $29,268
Internal Medicine $29,268
Dr. Sven Klauss, M.d, M.D
Internal Medicine — Payments: $19,876
Internal Medicine $19,876